Health Condition 1: C538- Malignant neoplasm of overlappingsites of cervix uteri
Conditions
Interventions
Intervention1: Nil: Nil
Sponsors
Saarthak Miglani
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients with histopathologically confirmed squamous cell carcinoma of cervix with FIGO stage IB3 to IVA 2. Eastern Co-operative Oncology Group (ECOG) performance score of less than or equal to 2
Exclusion criteria
Exclusion criteria: 1. Adenocarcinoma or other non-squamous histology of cervical cancer 2. Histopathologically proven squamous cell carcinoma of any site other than cervix 3. Synchronous malignancy 4. History of any previous malignancy or cancer directed treatment 5. Distant metastases 6. Haemoglobin less than 10 gm/dl 7. Liver function tests more than 3 times from the baseline 8. Chronic Kidney Disease Stage 3 9. Left Ventricular Ejection Fraction less than 45% 10. Pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Association of serum squamous cell carcinoma antigen levels with treatment response (as per WHO criteria) in cervical cancer patients staged FIGO IB3 to IVATimepoint: Baseline, at treatment completion, at 6 weeks post treatment completion and at 12 weeks post treatment completion | — |
Secondary
| Measure | Time frame |
|---|---|
| Association of serum squamous cell carcinoma antigen levels with FIGO stage, tumour size, lymph node status, parametrical invasion (unilateral vs bilateral), grade & histology (keratinising vs non-keratinising)Timepoint: At baseline, at treatment completion, at 6 weeks post treatment completion & 12 weeks post treatment completion | — |
Countries
India
Contacts
Public ContactSavita Arora
Maulana Azad Medical College
Outcome results
None listed